|
[Greeting] [Title] [Name],
|
|
I’m sorry I missed you earlier, but we should still connect to discuss the unmet needs your patients with Parkinson’s disease (PD) are facing.
|
|
Start the conversation
|
| |
|
|
|
Current treatments do little to address the variable nature of PD1
|
|
|
|
|
|
Dosing strategies with current carbidopa/levodopa (CD/LD) tablets put patients at risk of imprecise dosing2
|
|
|
|
|
|
Patients with PD need a better way to personalize their treatment
|
|
|
|
Please let me know what time is best for you and we can set up another [call/meeting]. I look forward to learning more about your practice and experiences with your PD patients.
|
|
Understanding their unique needs
|
|
Feel free to reach me at:
|
|
[rep email] | [rep phone number]
|
|
Sincerely,
|
|
[rep name]
|
|
[rep title]
|
|
[rep photo]
|
|
|
References: 1. Stoker TB, Greenland JC, eds. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; 2018.
2. Chaudhri K, Kearney M, Di Tanna GL, Day RO, Rodgers A, Atkins ER. Does splitting a tablet obtain the accurate dose?: a systematic review protocol. Medicine (Baltimore). 2019;98(42):e17189. doi:10.1097/MD.0000000000017189.
|
|
|
